Table 1.

Cohort Characteristics by IBD Diagnosis

Variable	Overall (N = 500)	CD (N = 347)	UC (N = 145)	Indeterminant Colitis (N = 8)	P
Age, Avg (SD)	40.2 (13.1)	38.9 (12.1)	43.2 (15.0)	44.8 (14.4)	0.0006
Sex, N (%)					0.27
Male	219 (43.8)	145 (41.8)	69 (47.6)	5 (62.5)
Female	281 (56.2)	202 (58.2)	76 (52.4)	3 (37.5)
Race					0.26
White	394 (78.8)	266 (76.7)	122 (84.1)	6 (75.0)
African American	78 (15.6)	64 (18.4)	12 (8.3)	2 (25.0)
Asian	6 (1.2)	4 (1.2)	2 (1.4)	0
Other	18 (3.6)	11 (3.2)	7 (4.8)	0
Unknown	4 (0.8)	2 (0.6)	2 (1.4)	0
Smoking, N (%)					0.19
Yes	61 (12.3)	48 (13.9)	13 (9.1)	0
No	435 (87.7)	297 (86.1)	130 (90.9)	8 (100)
Duration of IBD, avg (SD)	14.0 (9.8)	14.9 (9.9)	11.8 (8.9)	13.5 (12.2)	0.003
Disease location
Isolated ileal		103 (29.7)
Ileocolonic		178 (51.3)
Isolated colonic		54 (15.6)
Perianal disease		69 (19.9)
Upper tract		2 (0.6)
Rectum			7 (4.8)
Left-sided			40 (27.4)
Extensive			16 (11.1)
Pancolitis			74 (51.4)
Unknown			8 (5.5)
Disease phenotype
Inflammatory		131 (37.8)
Penetrating		102 (29.4)
Stricturing		110 (31.7)
Unknown		4 (1.2)
Incontinence
Daytime	60 (12.0)	43 (12.4)	16 (11.0)	1 (12.5)	0.9
Evening	33 (6.6)	25 (7.2)	8 (5.6)	0	0.59
Any	71 (14.2)	50 (14.4)	20 (13.8)	1 (12.5)	0.97
Steroid exposure
Any/ever	342 (69.5)	157 (45.2)	95 (65.5)
Salicylates and sulfasalazine
Any/ever	289 (58.7)	183 (52.7)	106 (73.1)
Thiopurines
Any/ever	218 (44.3)	159 (45.8)	59 (40.7)
Methotrexate
Any/ever	63 (12.8)	49 (14.1)	14 (9.7)		0.0004
Biologic exposure
Any/ever	331 (66.2)	249 (71.8)	78 (53.8)	4 (50.0)